Compare SMG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMG | BLLN |
|---|---|---|
| Founded | 1868 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Agricultural Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2012 | N/A |
| Metric | SMG | BLLN |
|---|---|---|
| Price | $60.99 | $83.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $72.67 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 851.7K | 295.7K |
| Earning Date | 04-29-2026 | 03-04-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 504.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,016,500,000.00 | N/A |
| Revenue This Year | N/A | $45.89 |
| Revenue Next Year | $2.54 | $30.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $45.61 | $61.96 |
| 52 Week High | $72.35 | $138.70 |
| Indicator | SMG | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 57.40 |
| Support Level | $58.67 | $80.39 |
| Resistance Level | $64.72 | $86.01 |
| Average True Range (ATR) | 2.27 | 5.45 |
| MACD | -0.35 | 1.32 |
| Stochastic Oscillator | 15.28 | 88.13 |
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.